Desktop Genetics Ltd (DTG), a biotech company globally recognised for its leadership in gene-editing bioinformatics, acquired exclusive worldwide licensing rights for TIDE (Tracking of Indels by DEcomposition), from the Netherlands Cancer Institute (NKI). The TIDE technology will allow investigators to quantitatively assess genome editing on the DESKGEN Cloud, the free CRISPR design software from DTG.
TIDE is a web tool that rapidly calculates the efficiency of CRISPR using Sanger DNA sequencing data. The proprietary decomposition algorithm, also determines the frequency of different repair products in the cell population. TIDE was developed by the van Steensel lab and published in Nucleic Acids Research (Brinkman et al., 2014). The tool is the first of its kind for detecting genome editing-mediated indels and has been cited in over 150 publications.
TIDE will be added to the DESKGEN Cloud platform, which offers a CRISPR Knockin and CRISPR Knockout design tool, Genome Editor and Guide ...
